GPCR Therapeutics, Inc., a drug discovery firm concentrating on G Protein Coupled Receptors (GPCR) pairs, has began its part 2 trial within the U.S. for its lead small molecule asset, GPC-100. GPC-100 targets CXCR4, one of the prevalent chemokine GPCRs overexpressed in additional than 23 cancers.
This randomized, open-label part 2 examine assesses the efficacy of GPC-100 and propranolol, with and with out granulocyte colony-stimulating issue (G-CSF) for the mobilization of stem cells in sufferers with a number of myeloma present process autologous stem cell transplant.
Propranolol blocks beta adrenergic receptors, additionally a part of the GPCR Therapeutics household of proteins. G-CSF is a glycoprotein that stimulates the bone marrow to provide granulocytes and stem cells and launch them into the bloodstream. The trial is for as much as 40 grownup sufferers who will probably be enrolled at most cancers facilities within the U.S.
The trial will embody 10 scientific websites, with the University of Massachusetts Chan Medical School chosen as the primary scientific website to be activated. Muthalagu Ramanathan will function the principal investigator. Trial completion is anticipated to be in the summertime of 2024.
Omar Nadeem, scientific director of the Myeloma Mobile Therapies Program on the Dana-Farber Most cancers Institute, and a member of GPCR Therapeutics’ scientific advisory board, mentioned: “This trial is finding out novel methods for stem cell assortment in a number of myeloma, together with a non-G-CSF strategy and evaluating the position of propranolol in enhancing stem cell assortment yield. This might enable for improved affected person expertise by making the method extra environment friendly whereas limiting the toxicity of the presently utilized strategies.”
Pina Cardarelli, GPCR Therapeutics’ CSO and president of U.S. operations, mentioned: “It is a main milestone on our scientific journey to find particular mixtures of medicine which are extra efficacious for most cancers remedy, delivering higher affected person outcomes.”
A number of myeloma
A number of myeloma is a most cancers that varieties in a kind of white blood cell referred to as a plasma cell, which, when wholesome, assist struggle infections by making antibodies that acknowledge and assault germs. In a number of myeloma, cancerous plasma cells accumulate within the bone marrow and crowd out wholesome blood cells, not producing useful antibodies, however irregular proteins that may trigger issues, comparable to bone ache and kidney abnormalities.
In 2019, greater than 32,000 sufferers within the U.S. have been diagnosed with this disease, with a median age of 68 years at analysis.